Lenalidomide is an oral non-chemotherapy immunomodulator with direct and indirect effects on non-Hodgkin lymphoma (NHL) cells and with single-agent activity in relapsed/refractory aggressive and indolent B-cell NHL, including mantle cell lymphoma (MCL), diffuse large B-cell lymphoma, and follicular lymphoma. Based on the pivotal phase II MCL-001 trial of lenalidomide in heavily pretreated patie...

background : there are only a few reports that exist regarding primary non-hodgkin lymphoma of the genital tract. in this article, one case of primary b-cell type non-hodgkin lymphoma (nhl) of the cervix is presented. case history: a 45 year-old woman presented bloody vaginal  discharge. upon vaginal examination, the cervix was found to be enlarged. cervical biopsy revealed b-cell type non-hodg...

Primary central nervous system (CNS) lymphoma is a rare form of primary brain neoplasm, in which ninety percent of cases are diffuse large B-cell lymphoma. HL involving the CNS is a rare event happening most of them in the context of relapsed systemic disease [1,2]. Primary CNS-hodgkin lymphoma (CNS-HL) is very rare, occurring in less than 0.2% of all HL cases [3], and it has been poorly report...

UNLABELLED We present here a systematic analysis of lymphoma and MM patients recruited into 2 clinical trials or treated with radretumab according to compassionate use, describing the biodistribution, dosimetry, safety, and clinical activity of radretumab. METHODS Uptake in lymphoma lesions, safety, and clinical activity of radretumab radioimmunotherapy (R-RIT) were evaluated in 18 relapsed l...

Brentuximab vedotin (BV) is approved for the treatment of patients with relapsed or refractory CD30-positive Hodgkin lymphoma, and relapsed or refractory systemic anaplastic large-cell lymphoma. Several uncertainties remain regarding the optimal use of the drug in its approved indications as well as outside them. This article reports recommendations on the use of BV issued during a consensus pr...

Mantle cell lymphoma is one of the most challenging hematologic malignancies, owing to an aggressive disease course, a high rate of relapse, and lack of standard of care. In the United States, mantle cell lymphoma accounts for approximately 6% of all newly diagnosed cases of non-Hodgkin lymphoma. Because most patients are initially diagnosed with advanced-stage disease, they are often symptomat...

Up to 40% of patients with advanced Hodgkin lymphoma (HL) become refractory or relapsed after current standard chemotherapy, among which primary refractory HL confers a particularly poor outcome. With intensive salvage chemotherapy and autologous stem cell transplantation, the long-term remission rate for these patients was only 30%, but more selective treatments with higher therapeutic index a...

We report a patient who developed up to three different lymphomas with the same clonal IGH rearrangement. She was first diagnosed of splenic zone marginal lymphoma and relapsed for the first time with Hodgkin lymphoma histology and later with diffuse large B-cell lymphoma histology. Subsequent biopsies and analysis of clonally rearranged IGH genes helped to elucidate the clonal relationship bet...

Current treatment of hematologic malignancies involves rather unspecific chemotherapy, frequently resulting in severe adverse events. Thus, modern clinical research focuses on compounds able to discriminate malignant from normal tissues. Being expressed in newly formed blood vessels of solid cancers but not in normal mature tissues, the extradomain B of fibronectin (ED-B FN) is a promising targ...

non-hodgkin lymphoma usually presents with generalized lymphadenopathy, but it can also involve any part of the human body. lymphomatous involvement of muscles is a rare presentation and has been reported to occur in only 1.1% in non-hodgkin lymphoma. here we, present a 32 year-old iranian man with primary involvement of spleen, bone, bone marrow and muscle, mimicking soft tissue sarcoma; core ...